C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy Design Randomisation * 2 : 1 Double blind W12 W16 W24 W28 > 18 years HCV infection Genotype 1, 4, 6 HCV RNA ≥ 10 000 IU/mL Treatment-naïve ≥ 3 months opioid replacement Compensated cirrhosis allowed HIV co-infection allowed N = 201 GZR/EBR 100/50 mg qd Placebo GZR/EBR (N = 95) N = 100 * Randomisation was stratified on genotype and cirrhosis (yes or no) Objective SVR12 (HCV RNA < 15 IU/mL) with 2 – sided 95% CI By intention to treat analysis: includes all patients, reinfection = failure By modified ITT (primary efficacy endpoint): reinfection = success Discontinuation without relapse considered as failure Superiority of immediate GZR/EBR (hypothesis of SVR12 ≥ 85%) vs reference rate of 67%, 99% power C-EDGE CO-STAR Dore GJ. Ann Intern Med 2016;165:625-636

Baseline characteristics and patient disposition C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy Baseline characteristics and patient disposition GZR/EBR N = 201 Placebo N = 100 Age, years, median 48 47 Female, % 24 23 Black / White / Asian, % 15 / 78 / 5 7 / 84 / 7 Genotype, % 1a 1b 4 6 76 15 6 2.5 75 15 6 4 IL28B CC, % 28.4 29.0 HCV RNA > 2 000 000 IU/mL, % 56.7 51.0 Fibrosis stage F4, % 19.9 22.0 HIV co-infection, % 8.0 5.0 Urine drug screen positive at D1, % 62.2 53.1 Discontinuation before W12 of follow-up (active phase), N Lost to follow-up For adverse event Administrative reason 5 3 1 7 7 0 0 C-EDGE CO-STAR Dore GJ. Ann Intern Med 2016;165:625-636

Primary endpoint: SVR12 (HCV RNA < 15 IU/mL), % (95% CI), ITT mFAS* C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy Primary endpoint: SVR12 (HCV RNA < 15 IU/mL), % (95% CI), ITT mFAS* Immediate GZR/EBR 100 75 50 25 94.0 (89.8-96.0) 95.5 (90.9-98.2) 93.3 (77.9-99.2) 91.7 (61.5-99.8) 60 (14.7-94.7) All patients Genotype 1a Genotype 1b Genotype 4 Genotype 6 201 154 30 12 5 % N= SVR12 , ITT, Full analysis set 91.5% 93.5% 93.3% 91.7% 20% Non-virologic failure 5 3 1 Relapse 7 4 2 Reinfection * ITT, mFAS: reinfection = success, unrelated discontinuation = excluded C-EDGE CO-STAR Dore GJ. Ann Intern Med 2016;165:625-636

Primary endpoint: SVR12 (HCV RNA < 15 IU/mL), % (95% CI), ITT mFAS* C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy Primary endpoint: SVR12 (HCV RNA < 15 IU/mL), % (95% CI), ITT mFAS* Deferred GZR/EBR 100 75 50 25 89.5 (81.5-94.8) 90.1 (80.7-95.9) 92.9 (66.1-99.8) (54.1-100) (6.8-93.2) All patients Genotype 1a Genotype 1b Genotype 4 Genotype 6 95 71 14 6 4 % N= SVR12 , ITT, Full analysis set 89.5% 90.1% 92.9% 100% 50% Non-virologic failure 7 6 1 Relapse Breakthrough 2 Reinfection * ITT, mFAS: reinfection = success, unrelated discontinuation = excluded C-EDGE CO-STAR Dore GJ. Ann Intern Med 2016;165:625-636

C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy SVR12 (HCV RNA < 15 IU/mL) in the immediate treatment group, by subgroup, % (95% CI), ITT, Full analysis set * Male Positive Negative No Yes Female 100 75 50 25 92.8 (87.5-96.4) 90.4 (84.2-94.8) 93.8 (85-98.3) 91.3 (85.8-95.2) 92.5 (79.6-98.4) 153 136 65 161 40 % 48 88 87.5 (74.8-95.3) 92.0 (84.3-96.7) 91.2 (84.3-95.7) 113 Sex Drug screen Cirrhosis HCV RNA > 2 000 000 IU/mL * Reinfection = failure C-EDGE CO-STAR Dore GJ. Ann Intern Med 2016;165:625-636

SVR12 and SVR24 (HCV RNA < 15 IU/mL), %, per protocol C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy SVR12 and SVR24 (HCV RNA < 15 IU/mL), %, per protocol % Immediate treatment Deferred treatment 100 75 50 25 95.5 94.1 96.6 SVR12 198 88 85 186 SVR24 96.5 N= C-EDGE CO-STAR Dore GJ. Ann Intern Med 2016;165:625-636

C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy Urine drug screen results, from D1 to treatment W12 At each visit, in both groups > 50% of patients with positive urine drug screen of any drug among the 8 following classes: amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, phencyclidine, propoxyphene Positive UDS results at baseline or during treatment (2 or more positive UDS results) did not affect adherence or efficacy, regardless of which drug class was positive on UDS Adherence to study drugs Immediate GZR/EBR Deferred GZR/EBR Placebo phase Active phase Adherence > 95% during the 12 weeks 96.5% 100% 95.8% C-EDGE CO-STAR Dore GJ. Ann Intern Med 2016;165:625-636

C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy SVR12 and urine drug screen results in the immediate treatment group (all randomised patients) Subgroup SVR12 n/N % (95% CI) Opiod agonist therapy at D1 Buprenorphine Methadone 37/39 147/162 94.9 (82.7-99.4) 90.7 (85.2-94.7) Drug screen during the treatment period Positive (at least 2 time points) Negative 123/136 61/65 90.4 (84.2-94.8) 93.8 (85.0-98.3) C-EDGE CO-STAR Dore GJ. Ann Intern Med 2016;165:625-636

C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy Reinfection 3.0 1.0 0.0 2.0 Reinfections Virologic failures TW10 or 12 FW4 FW8 FW12 FW24 % Reinfection, N (%) 0 (0.0) 5 (1.7) 1 (0.3) Virologic failure, N (%) 2 (0.7) 3 (1.0) Incidence of reinfection 4.6 reinfections (CI, 1.7 to 10.0) per 100 person-years 6 reinfections: different genotype, subtype or viral strain Dore G. EASL 2016, Abs. SAT-163, J Hepatol 2016;64:S771 ; Dore GJ. Ann Intern Med 2016;165:625-636 C-EDGE CO-STAR

C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy Summary of 18 patients with virological failure or probable reinfection Age, sex, cirrhotic status HCV RNA Genotype Drug screen Type/Time of failure 61-y, white male, cirrhosis 5.6 million IU/mL 1a Positive Relapse follow-up W12 50-y, black male, cirrhosis 13.6 million IU/mL Negative Relapse follow-up W4 56-y, male, no cirrhosis 1.2 million IU/mL Relapse follow-up W8 63-y, white female, no cirrhosis 3.5 million IU/mL 63-y, black female, no cirrhosis 1.7 million IU/mL 1b 29-y, asian male, no cirhhosis 33.2 million IU/mL 6a 34-y, asian male, no cirrhosis 25.5 million IU/mL 29-y, white female, no cirrhosis 335 157 IU/mL Not done Relapse follow-up W24 50-y, black female, cirrhosis 9.5 million IU/mL 58-y, black male, cirrhosis 2.8 million IU/mL Breakthrough W12 59-y, asian male, no cirrhosis 1.9 million IU/mL 6b 43-y, asian male, no cirrhosis 6.8 million IU/mL 48-y, asian male, no cirrhosis 17 274 IU/mL Reinfection (GT 6a) FU W8 33-y, white female, no cirrhosis 535 293 IU/mL Reinfection (GT 1a) FU W8 55-y, white female, cirrhosis 3.2 million IU/mL Reinfection (GT 3a) FU W8 45-y, asian male, no cirrhosis 4.8 million IU/mL Reinfection (GT 1b) FU W8 37-y, asian female, no cirrhosis 18.6 million IU/mL 33-y, white male, no cirrhosis 1.5 million IU/mL Reinfection (GT 3a) FU W24 C-EDGE CO-STAR Dore GJ. Ann Intern Med 2016;165:625-636

per 100 person-years (95% CI) C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy Reinfection during post-treatment and follow-up (3 years post-treatment) Reinfections N Follow-up person-years Reinfection rate per 100 person-years (95% CI) All persons 10 565 1.8 (0.8 – 3.3) Post-treatment to 3 years-follow-up Persons who reported IDU Persons who did not report IDU 6 1 212 316 2.8 (1.0 – 6.2) 0.3 (0.0 – 1.8) IDU = intravenous drug use C-EDGE CO-STAR Dore GJ. Ann Intern Med 2016;165:625-636 ; Grebely J. AASLD 2018 ; Abs. 52

C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy Reinfection 3.0 1.0 0.0 2.0 Reinfections Virologic failures TW10 or 12 FW4 FW8 FW12 FW24 % Reinfection, N (%) 0 (0.0) 5 (1.7) 1 (0.3) Virologic failure, N (%) 2 (0.7) 3 (1.0) Incidence of reinfection 4.6 reinfections (CI, 1.7 to 10.0) per 100 person-years 6 reinfections: different genotype, subtype or viral strain Dore G. EASL 2016, Abs. SAT-163, J Hepatol 2016;64:S771 ; Dore GJ. Ann Intern Med 2016;165:625-636 C-EDGE CO-STAR

C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy Adverse events, % GZR/EBR N = 201 Deferred GZR/EBR Placebo phase N = 100 Active phase N = 95 Serious adverse event 3.5 4.0 3.0 Serious drug-related adverse event 0.5 1.0 Adverse event leading to discontinuation Most frequent adverse events Fatigue 15.9 20.0 13.7 Headache 12.4 13.0 12.6 Nausea 10.9 9.0 7.4 AST/ALT > 3 x ULN 2 Total bilirubin > 2.6 x ULN Hemoglobin < 8.5 g/dL 1 1.1 Creatinine > 2.5 times baseline level C-EDGE CO-STAR Dore GJ. Ann Intern Med 2016;165:625-636

C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy Summary EBR/GZR demonstrated high efficacy in genotype 1 and 4-infected patients receiving opiate agonist therapy Limitation: small number of genotype 6-infected patients Acceptable safety profile with comparable adverse event rates between the immediate and deferred treatment arms High study medication adherence Stable ongoing drug use throughout the initial treatment phase in both groups Reinfection rate is higher in the immediate follow-up period These results support the removal of drug use as a barrier to interferon-free HCV treatment for patients receiving opiate agonist therapy C-EDGE CO-STAR Dore GJ. Ann Intern Med 2016;165:625-636

3-year Follow-up on Risk Factors and Rate of Reinfection C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy 3-year Follow-up on Risk Factors and Rate of Reinfection Observational cohort (6-month follow-up visits) Follow-up of 199/296 (67%) patients enrolled in Co-STAR Positive urine drug screen (UDS) at enrollment: 56% and 58% of patients in the 3YFU study and the Phase 3 trial, respectively Median time from EOT to the first visit during the 3YFU was 330 days (range: 206-485) 84 (56%) patients reported any drug use (non-injecting or injecting) in the past 6 months. Injecting drug use in the past 6 months was reported by 25% of patients Reinfection rate : higher in the immediate follow-up period through week (FW)12 (N = 5) than in the period through FW24 (+1) and through the ongoing observational follow-up Overall reinfection rate through the 6-month follow-up period is 4.0/100 person-years (N = 8) [ 95% CI : 1.7-8.0] Including only those patients with persistence of viremia (N = 5), the effective reinfection rate is 2.5/100 person-years [95% CI : 0.8-5.9] These data support addressing barriers in the treatment of patients on opiate agonist therapy and patients with ongoing drug use C-EDGE CO-STAR Dore GJ. AASLD 2016, Abs. 871